Aim immunotech submits ind and accompanying fast track application for phase 2 trial of ampligen in patients with locally advanced or metastatic late-stage pancreatic cancer

Ocala, fla., oct. 19, 2021 (globe newswire) -- aim immunotech inc. (nyse american: aim) today announced that it has submitted an investigational new drug application (ind) and an accompanying application for fast track status with the u.s. food and drug administration (fda) for a planned phase 2 study of the company's drug ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer.
AIM Ratings Summary
AIM Quant Ranking